Biologicals: Principles, techniques and mechanisms of action

Acta Gastro-Enterologica Belgica

Volumn 64, Issue 2, 2001, Pages 165-169

  Sands, B E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; GENE THERAPY; HUMAN;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; BIOLOGICAL THERAPY; CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; OLIGONUCLEOTIDES, ANTISENSE; T-LYMPHOCYTES, REGULATORY;

EID: 0034946503     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. SANDS B.E. Biologic therapy for inflammatory bowel disease. Inflamm. Bowel Dis., 1997, 3 (2) : 95-113.
2. VAN DEVENTER S.J.H., CAMOGLIO L. Monoclonal antibody therapy of inflammatory bowel disease. Aliment Pharmacol. Ther., 1996, 10 (Suppl. 2) : 107-111.
3. ASKARI F.K., MC DONNELL W.M. Antisense-oligonucleotide therapy. NEJM, 1996, 334 (5) : 316-318.
4. KRZYMANSKI M, WAAGA AM, ULRICHS K. et al. The influence of MHC class II antigen blockade by perfusion with a monclonal antibody on rat renal graft survival. Transplant International, 1991, 4 (3) : 180-185.
5. KRUIS W, SCHUTZ E, FRIC P, FIXA B, JUDMAIER G, STOLTE M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol. Ther., 1997, 11 (5) : 853-858.
6. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonie Crohn's disease ? J. Clin. Gastroenterol., 1997, 25 (4) : 653-658.
7. REMBACKEN B.J., SNELLING A.M., HAWKEY P.M., CHALMERS D.M., AXON A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis : a randomised trial. Lancet, 1999, 354 (9179) : 635-639.
8. GIONCHETTI P., RIZZELLO F., VENTURI A. et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis : a double-blind, placebo-controlled trial. Gastroenterology, 2000, 119 (2) : 305-309.
9. GUSLANDI M., MEZZI G., SORGHI M., TESTONI P.A. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci., 2000, 45 (7) : 1462-1464.
10. CUMMINGS J.H. Dietary carbohydrates and the colonic microflora. Curr. Opin. Clin. Nutri. Metab. Care, 1998, 1 (5) : 409-414.
11. JANEWAY C.A., BOTTOMLY K. Signals and signs for lymphocyte responses. Cell, 1994, 76 : 275-285.
12. LENSCHOW D.J., SU G.H.T., ZUCKERMAN L.A. et al. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA, 1993, 90 : 11054-11058.
13. BOUSSIOTIS V.A., FREEMAN G.J., GRIEBEN J.G., DALEY J., GRAY G., NADLER L.M. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA, 1993, 90 : 11059-11063.
14. STÜBER E., STROBER W., NEURATH M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med., 1996, 183 (2) : 693-698.
15. SHARMA S.D., NAG B., SU X.M. et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc. Natl. Acad. Sci. USA, 1991, 88: 11465-11469.
16. ABRAMS J.R., LEBWOHL M.G., GUZZO C.A. et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest., 1999, 103 (9) : 1243-1252.
17. DEUSCH K., MAUTHE B., REITER C., RIETHMÜLLER G., CLASSEN M. CD4-antibody treatment of inflammatory bowel disease : one-year follow up. Gastroenterology, 1993, 104 (4) : A691.
18. STRONKHORST A., RADEMA S., YONG S.L. et al. CD4 antibody treatment in patients with active Crohn's disease : a phase I dose finding study. Cut. 1997, 40 (3) : 320-327.
19. GROUX H., O'GARRA A., BIGLER M. et al. A CD4 sup + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389 (6652) : 737-742.
20. FUKAURA H., KENT S.C., PIETRUSEWICZ M.J., KHOURY S.J., WEINER H.L., HAFLER D.A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest., 1996, 98 (1) : 70-77.
21. YACYSHYN B.R., LAZAROVITS A., TSAI V., MATEJKO K. Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. Gastroenterology, 1994, 107 (5) : 1364-1371.
22. SANDS B.E., PODOLSKY D.K. The trefoil peptide family. Ann. Rev. Physiol., 1996, 58 : 253-273.